相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
Emily J. Faivre et al.
MOLECULAR CANCER RESEARCH (2017)
Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
Jianneng Li et al.
ELIFE (2017)
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Brian K. Albrecht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Organoid culture systems for prostate epithelial and cancer tissue
Jarno Drost et al.
NATURE PROTOCOLS (2016)
Hope for BET inhibition in patients with leukaemia or lymphoma
Mohamed A. Kharfan-Dabaja
LANCET HAEMATOLOGY (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
Howard I. Scher et al.
JAMA ONCOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Integrative analysis of 111 reference human epigenomes
Anshul Kundaje et al.
NATURE (2015)
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Mark M. Pomerantz et al.
NATURE GENETICS (2015)
NAR Breakthrough Article Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
Siu Chiu Chan et al.
NUCLEIC ACIDS RESEARCH (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo
Qiang Shao et al.
CANCER RESEARCH (2014)
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao et al.
CELL (2014)
Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
Wouter R. Karthaus et al.
CELL (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Irfan A. Asangani et al.
NATURE (2014)
Genome-wide localization of small molecules
Lars Anders et al.
NATURE BIOTECHNOLOGY (2014)
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Birgit Knoechel et al.
NATURE GENETICS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity
Changmeng Cai et al.
CELL REPORTS (2014)
Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
Masis Isikbay et al.
HORMONES & CANCER (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
Biswajyoti Sahu et al.
CANCER RESEARCH (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
Olivier Mirguet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Christopher J. Ott et al.
BLOOD (2012)
Small-Molecule Inhibition of BRDT for Male Contraception
Martin M. Matzuk et al.
CELL (2012)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
GENCODE: The reference human genome annotation for The ENCODE Project
Jennifer Harrow et al.
GENOME RESEARCH (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Caryn S. Ross-Innes et al.
NATURE (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
ChromHMM: automating chromatin-state discovery and characterization
Jason Ernst et al.
NATURE METHODS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions
Gabriel E. Zentner et al.
GENOME RESEARCH (2011)
A unique chromatin signature uncovers early developmental enhancers in humans
Alvaro Rada-Iglesias et al.
NATURE (2011)
Integrative genomics viewer
James T. Robinson et al.
NATURE BIOTECHNOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Jindan Yu et al.
CANCER CELL (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Menno P. Creyghton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse
Patrick O. McGowan et al.
NATURE NEUROSCIENCE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome
Ben Langmead et al.
GENOME BIOLOGY (2009)
Model-based Analysis of ChIP-Seq (MACS)
Yong Zhang et al.
GENOME BIOLOGY (2008)
Tumor suppressor activity of glucocorticoid receptor in the prostate
A. Yemelyanov et al.
ONCOGENE (2007)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
ME Gorre et al.
BLOOD (2002)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Characterization of promoter 1B in the human glucocorticoid receptor gene
BS Nunez et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2002)
分享论文
